🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

Science(2021)10.1126/science.abi4506Source: DataRank Database

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice is a research paper published in Science (2021). On theSindex it has a DataRank of 0. It has been cited 202 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access202 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (27 grants)Impact (FWCI 10.78)OA: hybridTopics (74)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Alexandra Schäfer ORCID,Sarah R. Leist ORCID,Gabriela De la Cruz ORCID,Ande West ORCID,Elena N. Atochina‐Vasserman ORCID

Live enrichment

PubMed:34214046 PMC:PMC8899822 OpenAlex:https://openalex.org/W3175969873

National Institutes of Health

Grant: AI157155

National Institutes of Health

Grant: HHSN272201700036I

Howard Hughes Medical Institute

Grant: Hanna H. Gray Fellowship

National Cancer Institute

Grant: U54CA260543

National Cancer Institute

Grant: 5P30CA016086-41

National Institute of Allergy and Infectious Diseases

Grant: AI007151

National Institute of Allergy and Infectious Diseases

Grant: AI152296

National Institute of Allergy and Infectious Diseases

Grant: AI124429

National Institute of Allergy and Infectious Diseases

Grant: AI142759

National Institute of Allergy and Infectious Diseases

Grant: R01AI132178

National Institute of Allergy and Infectious Diseases

Grant: AI100625

National Institute of Allergy and Infectious Diseases

Grant: AI108197

Burroughs Wellcome Fund

Grant: Postdoctoral Enrichment Award

Wellcome

Grant: NIH NIAID T32 AI007151

Wellcome

Grant: NIAID F32 AI152296

NIAID NIH HHS

Grant: F32 AI152296

NIAID NIH HHS

Grant: R01 AI124429

NIAID NIH HHS

Grant: U01 AI149644

NIAID NIH HHS

Grant: R01 AI157155

NIAID NIH HHS

Grant: U19 AI142759

NIAID NIH HHS

Grant: R01 AI110700

NIAID NIH HHS

Grant: U19 AI100625

NIAID NIH HHS

Grant: T32 AI007151

NCI NIH HHS

Grant: P30 CA016086

NIAID NIH HHS

Grant: R01 AI108197

Wellcome Trust

Wellcome Trust

FWCI

10.78

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1126/science.abi4506

publisherhttps://doi.org/10.1126/science.abi4506

publisherhttps://syndication.highwire.org/content/doi/10.1126/science.abi4506

publisherhttps://www.science.org/doi/pdf/10.1126/science.abi4506

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34214046

Fields of Study

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral Infections and Immunology ResearchAnimalsAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCOVID-19COVID-19 VaccinesCoronavirus InfectionsCross ProtectionCytokinesFemaleImmunity, HeterologousImmunogenicity, VaccineLiposomesLungMiceMice, Inbred BALB CNanoparticlesProtein DomainsRecombinant Fusion ProteinsSevere acute respiratory syndrome-related coronavirusSARS-CoV-2Severe Acute Respiratory SyndromeSpike Glycoprotein, CoronavirusVaccines, SyntheticViral VaccinesVirus ReplicationmRNA Vaccines

MeSH Terms

Immunogenicity, VaccineProtein DomainsBetacoronavirusCOVID-19SARS-CoV-2COVID-19 VaccinesmRNA VaccinesAnimalsAntibodies, ViralFemaleLiposomesLungMice, Inbred BALB CRecombinant Fusion ProteinsVaccines, SyntheticViral VaccinesVirus ReplicationCytokinesCoronavirus InfectionsSevere Acute Respiratory SyndromeSevere acute respiratory syndrome-related coronavirusMiceNanoparticlesCross ProtectionAntibodies, NeutralizingSpike Glycoprotein, CoronavirusImmunity, Heterologous

Keywords

CoronavirusVirologyPandemicBiologySpike ProteinSpike (software development)Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronaviridaeMessenger RNAFusion proteinGeneMedicineRecombinant DNAInfectious disease (medical specialty)GeneticsDisease

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (10)

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

N/A

1.1DataRank · unranked

Science(2020)

co-citedsame journal

10.1126/science.abd0826

A pneumonia outbreak associated with a new coronavirus of probable bat origin

N/A

1.5DataRank · unranked

Nature(2020)

co-cited

10.1038/s41586-020-2012-7

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

N/A

1.4DataRank · unranked

New England Journal of Medicine(2020)

co-cited

10.1056/nejmoa2034577

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

N/A

1.4DataRank · unranked

Cell(2020)

co-cited

10.1016/j.cell.2020.02.058

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

N/A

1.4DataRank · unranked

New England Journal of Medicine(2021)

co-cited

10.1056/nejmoa2035389

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

N/A

1.1DataRank · unranked

Nature(2020)

co-cited

10.1038/s41586-020-2456-9

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

N/A

1.1DataRank · unranked

Nature(2020)

co-cited

10.1038/s41586-020-2169-0

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

N/A

16.3DataRank · unranked

Nature(2020)

co-cited

10.1038/s41586-020-2852-1

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

N/A

1.1DataRank · unranked

Nature(2020)

co-cited

10.1038/s41586-020-2622-0

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

N/A

9.3DataRank · unranked

Nature(2020)

co-cited

10.1038/s41586-020-2639-4